VTGN
Vistagen Therapeutics, Inc.
+0.01 (+3.17%)0.24USD225K成交股數10.5M市值–本益比(近四季)4.2股價營收比+504.9%營收年增(近四季)2026-11-12下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 3 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 27Q1 | 26Q3 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 1.5M-9940% | 303K+29% | 258K+41% | 244K+190% | −15K-104% | 234K-16% | 183K+3% | 84K-52% | 411K | 278K | 177K | 176K |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 10.9M | 14.2M | 15.9M | 11.7M | 10.2M | 11.3M | 10.2M | 7.6M | 4.5M | 3.9M | 4.2M | 9.3M |
| 銷售管理費用 | 3.9M | 5.6M | 4.4M | 4.4M | 4.3M | 4.0M | 4.2M | 4.6M | 3.8M | 3.2M | 3.0M | 3.1M |
| 營業利益 | −13.3M-8% | −19.5M+29% | −20.1M+41% | −15.8M+30% | −14.5M+84% | −15.1M+123% | −14.2M+103% | −12.1M-1% | −7.9M | −6.8M | −7.0M | −12.2M |
| 營業利益率 | -904.3% | -6,450.8% | -7,772.5% | -6,477.0% | 96,633.3% | -6,461.5% | -7,774.3% | -14,441.7% | -1,918.2% | -2,438.8% | -3,953.7% | -6,954.0% |
| 稅後淨利 | −13.0M-4% | −18.9M+34% | −19.4M+50% | −15.1M+41% | −13.6M+115% | −14.1M+114% | −13.0M+88% | −10.7M-12% | −6.4M | −6.6M | −6.9M | −12.2M |
| 淨利率 | -882.8% | -6,237.3% | -7,526.0% | -6,186.5% | 90,900.0% | -6,020.9% | -7,082.5% | -12,777.4% | -1,545.0% | -2,369.8% | -3,900.0% | -6,947.2% |
| 稀釋 EPS | -0.30-32% | -0.45-2% | -0.54+29% | -0.47+34% | -0.44+100% | -0.46-30% | -0.42-55% | -0.35 | -0.22 | -0.66 | -0.94 | – |
| 稀釋股數 | 43.0M | 42.2M | 35.7M | 31.9M | 30.9M | 30.7M | 30.6M | 30.6M | 29.4M | 10.0M | 7.3M | – |
資產負債表 期末餘額
| 科目 | 27Q1 | 26Q3 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 17.0M | 47.4M | 62.8M | 49.0M | 67.1M | 74.7M | 84.2M | 103M | 127M | 37.6M | 9.6M | 16.6M |
| 應收帳款 | – | – | – | – | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 35.7M | 65.1M | 80.9M | 68.9M | 84.3M | 92.3M | 102M | 114M | 131M | 42.2M | 15.0M | 21.1M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 11.3M | 14.1M | 14.6M | 12.2M | 14.0M | 11.2M | 9.5M | 8.7M | 7.8M | 6.6M | 8.2M | 9.0M |
| 股東權益 | 24.5M | 50.9M | 66.3M | 56.8M | 70.4M | 81.1M | 93.0M | 105M | 123M | 35.6M | 6.8M | 12.1M |
| 負債比 | 31.5% | 21.7% | 18.0% | 17.6% | 16.5% | 12.1% | 9.3% | 7.7% | 5.9% | 15.5% | 54.4% | 42.7% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 27Q1 | 26Q3 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | −14.7M | – | – | −18.8M+73% | – | – | – | −10.9M | – | – | −7.9M | – |
| 資本支出 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流 | – | – | – | – | – | – | – | – | – | – | – | – |
| 折舊攤銷 | 52K | – | – | 40K | – | – | – | 34K | – | – | 32K | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解 2023 年度 10-K 的分部揭露 · 年增對前一年度
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2026 | 1.3M | +161.1% | −69.7M | -5,491.9% | -1.83 | – |
| FY2025 | 486K | -54.3% | −51.4M | -10,579.8% | -1.67 | – |
| FY2024 | 1.1M | -568.7% | −29.4M | -2,759.6% | -1.52 | −25.8M |
| FY2023 | −227K | -120.5% | −59.2M | 26,100.4% | -8.51 | −50.2M |
| FY2022 | 1.1M | +1.8% | −47.8M | -4,306.8% | – | −45.5M |
| FY2021 | 1.1M | – | −17.9M | -1,646.1% | -0.49 | −12.3M |
| FY2020 | 0.00 | -100.0% | −20.8M | –% | -0.50 | −15.8M |
| FY2019 | −8K | – | −24.6M | 307,370.0% | -0.90 | −14.7M |